Favourable result for temozolomide in recurrent high-grade glioma;Gunstig resultaat van temozolomide bij een recidief van een hooggradig glioom

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 25, 2005, Pages 1393-1399

  Taal, W ^a   Van Der Rijt, C D D ^a   Sillevis Smitt, P A E ^a   Kros, J M ^a   Van Heuvel, I ^a   Enting, R H ^a,b   Graveland, W J ^a   Van Den Bent, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

AGRANULOCYTOSIS; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CANDIDIASIS; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; OLIGODENDROGLIOMA; PNEUMONIA; RECURRENT CANCER; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 20844453600     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kros JM. Indeling en gradering van gliale tumoren. Ned Tijdschr Geneeskd 1996;140:292-7.
2. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003;361:323-31.
3. Bent MJ van den, Schellens JHM, Sillevis Smitt PAE, Vecht CJ. Chemotherapie bij hersentumoren. Ned Tijdschr Geneeskd 1996;140:702-6.
4. Bent MJ van den, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, et al. Chromosomal anomalies in oligodendro-glial tumors are correlated with clinical features. Cancer 2003;97: 1276-84.
5. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
6. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65:287-91.
7. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83: 588-93.
8. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-71.
9. Bent MJ van den, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors. The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003;21:2525-8.
10. Bent MJ van den, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy. EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003;14:599-602.
11. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12: 259-66.
12. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997; 40:484-8.
13. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996;32A:2236-41.
14. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
15. Vos MJ, Uitdehaag BM, Barkhof F, Heimans JJ, Baayen HC, Boogerd W, et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 2003;60:826-30.
16. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001;19:2449-55.
17. Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003;14: 1722-6.
18. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12:2013-21.
19. Bent MJ van den, Kros JM, Heimans JJ, Pronk LC, Groeningen CJ van, Krouwer HG, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51: 1140-5.
20. Rappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, Bent MJ van den, Groeningen CJ van, et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 2001;56:118-20.
21. Prados MD. Systemic chemotherapy. In: Bernstein M, Berger MS, editors. Neuro-oncology. The essentials. New York: Thieme Medical Publishers; 2000. p. 226-33.
22. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
23. Stupp R, Mason WP, Bent MJ van den, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.